NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
02/22/2025
Back to search
Official data from USPTO
ROYAL PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ROYAL PHARMACEUTICALS
ST13
US500000087112891Class
35
Filing
87112891
Registration
5387582
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
02/22/2025
Trademark type
Word
Nice classes
35
Filing date
07/22/2016
Registration date
01/23/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/22/2025
Last transaction
02/22/2025
Responsible office
United States Patent and Trademark Office
Status code
702
Official register
Principal Register
First use anywhere
08/01/2008
First use in commerce
08/01/2008
Drawing code
4
Owner type
16
Owner location
Wall, NJ
Examiner
KENEALY, NATALIE
Current location
Historical data usage
Holders and representatives
Holders
Royal Pharmaceuticals, LLC
Royal Pharmaceuticals, LLC
Representatives
Gregory F. Kotchick DURKIN & DURKIN, LLC
Technical classification
Nice Classes
Class 35
Vienna Codes
No Vienna codes available.
Goods and services
Class 35
Distributorships and wholesale distributorships and retail store services featuring branded FDA approved and unapproved pharmaceutical products and vitamins for sale to national distributorswholesalersretail chains and health systems
Publications
History of USPTO decisions and trademark events.
29 publications found
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
02/22/2025
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
02/04/2025
PR23
POST REGISTRATION ACTION MAILED - SEC. 8 & 15
08/07/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/03/2024
E815
TEAS SECTION 8 & 15 RECEIVED
01/18/2024
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/23/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
01/23/2018
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/19/2017
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/18/2017
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/13/2017
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/13/2017
IUAF
USE AMENDMENT FILED
11/30/2017
EISU
TEAS STATEMENT OF USE RECEIVED
11/30/2017
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
09/05/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/11/2017
PUBO
PUBLISHED FOR OPPOSITION
07/11/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/21/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/06/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/03/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/02/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/02/2017
ALIE
ASSIGNED TO LIE
05/26/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/04/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/09/2016
GNRT
NON-FINAL ACTION E-MAILED
11/09/2016
CNRT
NON-FINAL ACTION WRITTEN
11/09/2016
DOCK
ASSIGNED TO EXAMINER
11/02/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/28/2016
Continuous trademark protection
Get notified about every new filing that threatens ROYAL PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.